BioPharmSignal logoBioPharmSignal

Biotech News

Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Biotherapeutics, Inc. (IOVA)Iovance Biotherapeutics, Inc.Company update

SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior

Related news

IOVAIovance Biotherapeutics, Inc.2026-09-18 21:10 EST

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

IOVAIovance Biotherapeutics, Inc.2026-08-06 11:01 EST

Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates

SANASana Biotechnology2026-09-01 20:05 EST

Sana Biotechnology to Present at September 2026 Investor Conferences

ELVNEnliven Therapeutics2026-09-03 20:05 EST

Enliven Therapeutics to Present at Upcoming Investor Conferences

GERNGeron2026-09-02 12:00 EST

Geron to Present at Upcoming Investor Conferences

IMCRImmunocore Holdings plc2026-09-01 11:00 EST

Immunocore to present at upcoming investor conferences

ARGXArgenx2026-09-01 05:00 EST

argenx to Present at Upcoming Investor Conferences

CRSPCRISPR Therapeutics2026-09-08 12:30 EST

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

BMEABiomea Fusion2026-09-03 12:00 EST

Biomea Fusion to Participate in Upcoming Investor Conferences

TEVATeva Pharmaceutical Industries2026-09-01 20:30 EST

Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September

View all latest news

Iovance Biotherapeutics, Inc.

Tumor-Infiltrating Lymphocyte Therapy Iovance Biotherapeutics develops and commercializes autologous tumor-infiltrating lymphocyte therapies for solid tumors. Patient T cells are isolated from a tumor, expanded and reinfused following lymphodepletion. Amtagvi Amtagvi, or lifileucel, is approved in the United States for selected patients...

Recent company news

IOVAIovance Biotherapeutics, Inc.2026-09-18 21:10 EST

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

IOVAIovance Biotherapeutics, Inc.2026-09-04 12:00 EST

Iovance Biotherapeutics to Present at Upcoming Conferences

IOVAIovance Biotherapeutics, Inc.2026-08-21 21:15 EST

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

IOVAIovance Biotherapeutics, Inc.2026-08-06 11:01 EST

Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates

IOVAIovance Biotherapeutics, Inc.2026-07-30 12:00 EST

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

Stock data

Close
10.02 USD
Market cap
1.83B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States